TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00006929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suramin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01065558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam
Description: Tablets, once daily, for two weeks up to 200 mg/day
Study: NCT04056949

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel/Albumin-Bound Paclitaxel
Description: Paclitaxel 175mg/m2 IV on day 1of 21 days cycle ;Number of Cycles: 4-6; or Albumin-bound paclitaxel 130mg/m2 IV on day 1 and 8 of 21 days cycle ;Number of Cycles: 4-6;

Intervention type: DRUG
Group type: OTHER
Intervention: IBI308
Description: IBI308 200mg IV infusion, every 3 weeks,until disease progress or intolerable toxicity,used up to 1 year (or 16 cycles)
Study: NCT04712409

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single anastomosis duodeno-ileal bypass
Description: Sleeve gastrectomy followed by division of the duodenum bypassing the jejunum with end-to-side duodeno-ileal diversion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biliopancreatic diversion with duodenal switch
Description: Sleeve gastrectomy, followed by division of the duodenum bypassing the jejunum with end-to-side duedeno-ileal diversion and Roux-en-y entero-enteric anastomosis, leaving 100 cm common channel.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SADI-S as a revisional procedure
Description: In patients previously submitted to sleeve gastrectomy a single anastomosis duodeno-ileal bypass will be performed as 2nd time surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BPD-DS as a revisional procedure
Description: In patients previously submitted to sleeve gastrectomy a biliopancreatic diversion with duodenal switch will be performed as 2nd time surgery
Study: NCT02763319

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab (RTX)
Description: Rituximab: Dose: 375 mg/m2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Tafasitamab: Tafasitamab dose: 12 mg/kg intravenously (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine (BEN)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine (BEN)
Study: NCT00437476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/r
Description: Lopinavir/Ritonavir 200/50 mg 2 cpr BID monotherapy - 26 weeks (A) or 24 weeks (B)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LPV/r
Description: Lopinavir/Ritonavir 200/50 mg 2 cpr BID monotherapy - 26 weeks (A) or 24 weeks (B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nucleoside Reverse Transcriptase Inhibitors
Description: NRTIs for 26 weeks (A) or 24 weeks (B)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nucleoside Reverse Transcriptase Inhibitors
Description: NRTIs for 26 weeks (A) or 24 weeks (B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFNa 2a
Description: PEG-IFNa 2a 180 mcg/week (48 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-IFNa 2a
Description: PEG-IFNa 2a 180 mcg/week (48 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin 1-1.2 g/day (48 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin 1-1.2 g/day (48 weeks)
Study: NCT00335517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DepoDur
Description: An epidural catheter will be placed under direct vision at the conclusion of surgery. The catheter will be advanced at least 4cm to L1 level prior to injection. Two mililiters of air will be injected through the catheter to ensure patency. Aspiration will be done to ensure no intradural injections. Then the undiluted (1 or 1.5 cc) DepoDur will be injected.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DepoDur
Description: An epidural catheter will be placed under direct vision at the conclusion of surgery. The catheter will be advanced at least 4cm to L1 level prior to injection. Two mililiters of air will be injected through the catheter to ensure patency. Aspiration will be done to ensure no intradural injections. Then the undiluted (1 or 1.5 cc) DepoDur will be injected.
Study: NCT00787163

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: amnioinfusion
Description: serial amnioinfusions aimed at restoring amniotic fluid volume
Study: NCT04247165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 800 mg/m2 Day 1, 8, 15: Q4W IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: 100 mg/m2 Day 1, 8, 15: Q4W IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg Day 1, Q4W IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1 mg/kg Day 1 Cycle 1 IV Infusion

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patients will be planned and treated with SBRT on a MRidian MR guided Linac.~Prescription dose shall be according to the following specifications:~* Prescription dose shall be according to the following specifications:~* A total dose of 24 Gy in 3 fractions (3 fractions/week) are prescribed as the mean dose to the PTV.~* Pauses are accepted but the treatment should be delivered within 10 calendar days.~* PTV should be covered by 95% isodose (PTV D99% \>95%).
Study: NCT00578279

Intervention type: DRUG
Group type: OTHER
Intervention: dehydrated alcohol
Description: subject randomized to 10ml or 20ml of dehydrated alcohol one time during the EUS-CPN procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dehydrated alcohol
Description: subject randomized to 10ml or 20ml of dehydrated alcohol one time during the EUS-CPN procedure
Study: NCT03313531

Intervention type: DIAGNOSTIC_TEST
Intervention: Thrombin Generation Assay
Description: Inter lab variation and level of agreement will be determined

Intervention type: DIAGNOSTIC_TEST
Intervention: Thrombin Generation Assay
Description: Inter lab variation and level of agreement will be determined

Intervention type: DIAGNOSTIC_TEST
Intervention: Thrombin Generation Assay
Description: Inter lab variation and level of agreement will be determined

Intervention type: DIAGNOSTIC_TEST
Intervention: Thrombin Generation Assay
Description: Inter lab variation and level of agreement will be determined
Study: NCT04198727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DPD activity assessment
Description: Phenotyping DPD with enzyme activity measure and uracil dosage
Study: NCT03313531

Intervention type: DRUG
Intervention: Treatment with recombinant coagulation factor
Description: To obtain a wide range of thrombingeneration levels, one person (Treated HA person) will recieve one injection of Advate and one injection of Adynovate respectively
Study: NCT04582279

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung ultrasound
Description: The lung ultrasound will be performed by a trained pulmonologist by gently pressing a probe to various areas of your chest. This is a non-invasive procedure and you should not feel any pain. The ultrasound will take less than 10 minutes.
Study: NCT01222312

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m2, d1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m², d1 every 2 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2, d1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 50mg/m2, d1 every 2 weeks
Study: NCT01431313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitrite
Description: Each patient will receive a starting dose of 45 mg of inhaled nitrite, with one planned subsequent planned dose of 90 mg of inhaled nitrite
Study: NCT02586311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-330 16/5mg
Description: Once a day, 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine 5mg Placebo
Description: Once a day, 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CKD-330 16/5mg Placebo
Description: Once a day, 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 5mg
Description: Once a day, 8 weeks
Study: NCT04198727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine assignement at 1000mg per square meter twice daily, cycle of 21 days, 14 days of intake, 7 days of
Study: NCT02710487

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REMSA
Description: Awakening from REM sleep during the last hour of the sleep period

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NREMSA
Description: Awakening from N2 (NREM) sleep during the last hour of the sleep period
Study: NCT01205880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol ointment
Description: twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol spray
Description: twice daily
Study: NCT02541955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acthar
Description: Injections will be self administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acthar
Description: Injections will be self administered
Study: NCT00168428

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Two treatment sessions in the double-blind phase and three treatment sessions in the open-label phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo (saline)
Description: Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
Study: NCT04301739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide
Description: chemotherapeutics

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nab-paclitaxel, carboplatin, doxorubicin or epirubicin and cyclophosphamide
Description: chemotherapeutics

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04256564

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central venous catheterization
Description: A standard 20 cm (adult-size) 3-port central catheter will be placed to the indicated patients by using standard Seldinger technique (with the assist of a guide wire) under ultrasound guidance

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central venous catheterization
Description: A standard 20 cm (adult-size) 3-port central catheter will be placed to the indicated patients by using standard Seldinger technique (with the assist of a guide wire) under ultrasound guidance
Study: NCT02861664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stannous fluoride (SnF2)
Description: Dentifrice containing 0.454% weight by weight (w/w) SnF2 and 0.072% w/w NaF

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium monofluorophosphate (SMFP)
Description: Dentifrice containing 1400 ppm fluoride as SMFP
Study: NCT01268657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Learning about anxiety

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Training
Description: Learning skills to reduce tension

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring
Description: Learning skills needed to cope better with distressing thoughts

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Learning to initiate healthy activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure
Description: Coaching in how to confront avoided thoughts, situations, and people)
Study: NCT04219592

Intervention type: DIAGNOSTIC_TEST
Intervention: IgG4 measurement (non-interventional, just obtaining data from medical records)
Description: IgG4 measurement in mg/dL

Intervention type: DIAGNOSTIC_TEST
Intervention: IgG4 measurement (non-interventional, just obtaining data from medical records)
Description: IgG4 measurement in mg/dL
Study: NCT02063594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCTX (PEGylated Liposomal Iodixanol Injection)
Description: Single dose of NCTX (PEGylated Liposomal Iodixanol Injection) administered at escalating doses from 9 mg I/kg up to 110 mg I/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: Single dose of 0.9% Sodium Chloride Injection, USP administered similarly and at an equivalent dose volume as the active drug
Study: NCT04323384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biotene® Oralbalance Moisturizing Gel
Description: Biotene® Oralbalance Moisturizing Gel will be applied to the oral cavity according to the package directions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biotene® Oralbalance Moisturizing Gel
Description: Biotene® Oralbalance Moisturizing Gel will be applied to the oral cavity according to the package directions.
Study: NCT02603211

Intervention type: DEVICE
Intervention: tactile imaging sensor or system made in our laboratory
Description: This is a camera with elastomer tip and LED lights. It is a harmless device.
Study: NCT04232644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADAIR 10mg IR capsules
Description: manipulated ADAIR IR 3x10 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADAIR 10mg IR capsules
Description: manipulated ADAIR IR 3x10 mg capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crushed d-amphetamine sulfate IR tablets
Description: crushed d-amphetamine sulfate IR 6 x 5 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crushed d-amphetamine sulfate IR tablets
Description: crushed d-amphetamine sulfate IR 6 x 5 mg tablets
Study: NCT03822156

Intervention type: OTHER
Intervention: Observation of AFB smear/culture
Description: Observation of the patients from group for their AFB smear/culture results

Intervention type: OTHER
Intervention: Observation of AFB smear/culture
Description: Observation of the patients from group for their AFB smear/culture results
Study: NCT03939923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Intubation with Rocuronium 1.0-1.2 mg/kg (vitals maintained within 20% of baseline. Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Intubation with Rocuronium 1.0-1.2 mg/kg (vitals maintained within 20% of baseline. Subjects may be re-dosed with rocuronium at 0.1-0.4 mg/kg during the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Reversal with neostigmine (0.04-0.07 mg/kg up to 5 mg maximal dosage)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: Reversal glycopyrrolate (0.07-0.015mg/kg up to 1 mg maximal dosage)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Reversal with Sugammadex (2mg/kg)
Study: NCT01947842

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone App Dosecast
Description: The Dosecast app is configured to remind the patient to take their medication.
Study: NCT04461548

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Thinking, writing and imagining
Description: All participants are asked to take some time to think and write about the content of the respective intervention group. After the writing exercise (approx. 15-20 min) participants are asked to imagine that content for about 5 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thinking, writing and imagining
Description: All participants are asked to take some time to think and write about the content of the respective intervention group. After the writing exercise (approx. 15-20 min) participants are asked to imagine that content for about 5 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thinking, writing and imagining
Description: All participants are asked to take some time to think and write about the content of the respective intervention group. After the writing exercise (approx. 15-20 min) participants are asked to imagine that content for about 5 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thinking, writing and imagining
Description: All participants are asked to take some time to think and write about the content of the respective intervention group. After the writing exercise (approx. 15-20 min) participants are asked to imagine that content for about 5 minutes.
Study: NCT01301300

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Disinfecting Cap
Description: Replace standard practice with using the disinfecting cap

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Disinfecting Cap
Description: Replace standard practice with using the disinfecting cap
Study: NCT02749227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR
Description: Pasireotide LAR (SIGNIFOR® LAR) is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. It is a long acting release injectable suspension for intramuscular use.~The starting dose is Pasireotide LAR 40 mg/month intramuscular (IM), this will be increased to 60 mg/month at 6 months if a fall in POMC levels and/or tumor shrinkage are not attained.
Study: NCT02364583

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: Primaquine treatment given in a step-wise manner; (a) 0.5 mg/kg total dose daily for 14 days (n=40), (b) 1.0 mg/kg total dose daily for 7 days (n=40), (c) 1.0 mg/kg twice daily for 3.5 days (n=40)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: Primaquine treatment given in a step-wise manner; (a) 0.5 mg/kg total dose daily for 14 days (n=40), (b) 1.0 mg/kg total dose daily for 7 days (n=40), (c) 1.0 mg/kg twice daily for 3.5 days (n=40)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine
Description: Primaquine treatment given in a step-wise manner; (a) 0.5 mg/kg total dose daily for 14 days (n=40), (b) 1.0 mg/kg total dose daily for 7 days (n=40), (c) 1.0 mg/kg twice daily for 3.5 days (n=40)
Study: NCT02136901

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NUsurface® Meniscus Implant
Description: The NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID's and Non-surgical Treatment Options
Description: Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-Articular Injections with Corticosteroids
Description: Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-Articular Injections with Hyaluronic Acid (HA)
Description: Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
Study: NCT01646840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242 capsule
Description: Single dose of PF-04958242 0.35 mg oral capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF-04958242 oral solution
Description: Single dose of PF-04958242 0.35 mg oral solution
Study: NCT03438084

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Interesterified fat
Description: 50 g fat provided as commercially available interesterified fat.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Non- interesterified fat
Description: 50 g fat provided as commercially available non-interesterified fat.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Rapeseed oil
Description: 50 g fat provided as commercially available rapeseed oil.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Butter
Description: 50g fat provided as commercially available spreadable butter
Study: NCT02753816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Study: NCT02872233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 987519
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF 15 Control
Description: Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.